Using S-nitrosoglutathione to treat lung disease in premature infants
Official title: S-Nitrosoglutathione therapy for oxidant disease of the neonatal airways and lung
Funded at Case Western Reserve University · NIH-11074687 · Data updated 2026-11-12
This study is looking at how a substance called GSNO might help improve lung problems in premature babies with bronchopulmonary dysplasia by reducing inflammation and making it easier for them to breathe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | April 15, 2024 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $533,073 |
| NIH project number | 5R01HL172894-02 |
| Project ID | NIH-11074687 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are premature infants diagnosed with bronchopulmonary dysplasia.
✕Less likely to help
Patients who are not premature or do not have bronchopulmonary dysplasia may not benefit from this research.
What this research studies
This research investigates the use of S-nitrosoglutathione (GSNO) as a potential therapy for bronchopulmonary dysplasia (BPD), a serious lung condition affecting premature infants. The study aims to understand how GSNO can reverse airway hyperresponsiveness caused by oxidative stress in the lungs. By utilizing a mouse model that mimics the condition, researchers will explore the mechanisms by which GSNO acts as a bronchodilator and anti-inflammatory agent. The findings could lead to new treatment options for infants suffering from this debilitating disease.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that improves lung function and reduces the risk of chronic respiratory issues in premature infants.
How similar studies have gone: Previous research has shown promising results with similar therapeutic approaches using GSNO in animal models, indicating potential for success in clinical applications.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Raffay, Thomas Michael — Case Western Reserve University
- Study coordinator: Raffay, Thomas Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.